These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29757706)

  • 1. The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.
    Suder E; Furuyama W; Feldmann H; Marzi A; de Wit E
    Hum Vaccin Immunother; 2018; 14(9):2107-2113. PubMed ID: 29757706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.
    Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA
    Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915
    [No Abstract]   [Full Text] [Related]  

  • 5. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
    Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
    Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
    Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
    PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
    Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
    mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.
    Dolzhikova IV; Zubkova OV; Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Tokarskaya EA; Simakova YV; Egorova DA; Scherbinin DN; Tutykhina IL; Lysenko AA; Kostarnoy AV; Gancheva PG; Ozharovskaya TA; Belugin BV; Kolobukhina LV; Pantyukhov VB; Syromyatnikova SI; Shatokhina IV; Sizikova TV; Rumyantseva IG; Andrus AF; Boyarskaya NV; Voytyuk AN; Babira VF; Volchikhina SV; Kutaev DA; Bel'skih AN; Zhdanov KV; Zakharenko SM; Borisevich SV; Logunov DY; Naroditsky BS; Gintsburg AL
    Hum Vaccin Immunother; 2017 Mar; 13(3):613-620. PubMed ID: 28152326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ebola vaccine trials: progress in vaccine safety and immunogenicity.
    Matz KM; Marzi A; Feldmann H
    Expert Rev Vaccines; 2019 Dec; 18(12):1229-1242. PubMed ID: 31779496
    [No Abstract]   [Full Text] [Related]  

  • 11. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
    Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2017 May; 91(10):. PubMed ID: 28250127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus.
    Wong G; Qiu X
    Methods Mol Biol; 2016; 1403():245-57. PubMed ID: 27076134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans.
    Poetsch JH; Dahlke C; Zinser ME; Kasonta R; Lunemann S; Rechtien A; Ly ML; Stubbe HC; Krähling V; Biedenkopf N; Eickmann M; Fehling SK; Olearo F; Strecker T; Sharma P; Lang KS; Lohse AW; Schmiedel S; Becker S; ; Addo MM
    J Infect Dis; 2019 Jan; 219(4):556-561. PubMed ID: 30452666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens.
    Fathi A; Dahlke C; Addo MM
    Hum Vaccin Immunother; 2019; 15(10):2269-2285. PubMed ID: 31368826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine.
    Wong G
    mBio; 2019 Jul; 10(4):. PubMed ID: 31311887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs.
    Locher S; Schweneker M; Hausmann J; Zimmer G
    J Gen Virol; 2018 Jul; 99(7):866-879. PubMed ID: 29869979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ebola vaccines - Where are we?
    Watle SV; Norheim G; Røttingen JA
    Hum Vaccin Immunother; 2016 Oct; 12(10):2700-2703. PubMed ID: 27548643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
    Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X
    Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.